TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A 2026 paper in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be understood as problems of the aging motor system, not muscle alone. The researchers say nerve and brain function may help explain why muscle size does not reliably predict strength, but they acknowledge that proposed tests have not yet been shown to improve outcomes.
A paper published in The Lancet Healthy Longevity argues that age-related weakness and loss of mobility should not be treated as muscle problems alone, but as possible effects of changes across the motor system, including the brain, spinal cord and nerves that control movement. The authors say the proposal could reshape how sarcopenia is assessed and researched, while acknowledging that the additional tests they recommend have not been shown to outperform current screening or improve patient outcomes.
The researchers say clinical definitions of sarcopenia have already moved beyond measuring muscle mass. Measures such as grip strength, walking speed and chair stands are used because they can better predict falls, disability and death than muscle size. But, they argue, the explanation for declining function has remained centered on muscle loss, even though muscle loss accounts for only a modest share of the strength decline observed with age.
The paper describes movement as the product of a chain running from the brain and spinal cord through nerves to muscle. Aging may affect how movements are planned, how reliably nerve signals travel and how well the body senses position and maintains balance. In this model, muscle may remain present, but the signals that recruit it may become weaker or less reliable. The authors point to standing from a chair as an example: the task depends on speed and power, not simply muscle bulk.
The authors propose that clinicians retain established measures of strength and gait while also investigating whether practical observations could add useful information. These include how quickly someone rises from a chair, whether they become unsteady during sustained effort, changes in hand dexterity, and walking performance while talking. They also recommend closer examination when weakness is asymmetric, rapid or disproportionate to apparent muscle loss. The paper says sedative and anticholinergic medicines can blunt motor drive, making medication review relevant alongside exercise and strength training.
Why Falls and Independence Matter
The proposed shift matters because weakness and mobility loss can affect whether older people remain able to manage daily tasks, avoid falls and live independently. The Medical Xpress report says sarcopenia affects up to 29% of older adults living in the community, with higher rates reported in hospitals, residential elder care and among people with frailty or multiple health conditions.
The report also gives the scale of falls in Australia: 253,800 fall-related hospitalizations in 2024–25, and 6,722 Australians died after falls in the preceding year. It cites an estimated A$5.4 billion cost to the health system from fall injuries. These figures describe the Australian setting; they do not establish that the proposed motor-system approach would reduce falls or costs.
If future studies validate broader assessments, clinicians may be better able to distinguish why a particular person is becoming weak and choose interventions that target more than muscle mass. The authors argue that research and care should measure strength, movement and everyday function, not assume that increasing muscle size alone will restore mobility.
Products Worth Considering
BowFlex SelectTech 840 Adjustable Kettlebell
Fitbit Versa 2 Health and Fitness Smartwatch with Bonus Bands
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Movement
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. It is linked with frailty, disability and reduced independence. In primary care, an Australian Journal of General Practice article published earlier in 2026 proposed an algorithm for screening, assessing and managing poor muscle health.
The new paper, by Lucas B. R. Orssatto and colleagues, responds to a gap between how sarcopenia is measured and how it is commonly explained. The authors say diagnostic practice increasingly relies on functional measures such as grip and gait, while research and treatment have continued to focus heavily on muscle. They argue that exercise can improve strength and mobility even when measurable muscle mass does not change, while some muscle-building drug and protein strategies have produced limited gains in everyday function.
The authors set out a five-point agenda for international working groups that develop diagnostic criteria. Their broader proposal is to treat the aging motor system as a possible source of weakness and to fund practical tests and trials that assess nerve function as well as muscle. The paper is a research argument and agenda, not a new clinical guideline establishing a replacement diagnosis.
“Nobody has yet shown that these measures beat existing screens, either on outcomes or on cost.”
— The paper’s authors
Tests Still Need Validation
The proposed motor-system framing remains an argument for research and changes in assessment, not proof that the new approach produces better care. The authors say the suggested measures have not been shown to outperform existing screens for patient outcomes or cost. It is also unclear which tests would be reliable and practical in routine primary care.
The report notes that access to neuromuscular expertise varies among primary care settings. The paper does not establish which patients would benefit from particular assessments, whether the proposed measures can identify a specific cause of weakness, or whether using them would reduce falls, disability or health-system spending. Nor does the source provide trial results showing that treatments aimed at nerves or other parts of the motor system improve everyday function.
The reported Australian fall statistics provide context about the burden of injury, but they do not show that sarcopenia or motor-system changes caused each fall. The authors call for validation and trials rather than claiming that their proposal has already changed diagnostic standards or clinical outcomes.
Research Agenda and Clinical Criteria
The authors call for investment in practical assessment tests that can be validated in clinical settings, guidelines that support a staged assessment approach, and trials measuring nerve function as well as muscle. International groups responsible for diagnostic criteria are the intended audience for their five-point agenda.
The next evidence needed is whether broader measures add useful information beyond current strength and mobility screens, whether clinicians can apply them consistently, and whether interventions guided by them improve function or prevent falls. Until those questions are answered, the paper supports further testing of the motor-system model; it does not establish a new standard of care.
Key Questions
What does the paper mean by the motor system?
It means the connected systems that produce movement, including the brain, spinal cord, nerves and muscles. The authors argue that age-related weakness may reflect changes across this system rather than muscle loss alone.
Does this paper change how sarcopenia is diagnosed?
No. The article presents a research proposal, not a new diagnostic guideline. The authors are asking international groups that set criteria to consider broader assessment and call for evidence to validate proposed tests.
What additional signs do the authors suggest observing?
They suggest looking at how quickly a person rises from a chair, balance during sustained effort, hand dexterity and walking while talking, alongside established measures such as grip strength and gait speed. They say these approaches still need testing.
Have the proposed assessments been shown to prevent falls?
The source does not report evidence that the proposed assessments prevent falls or improve outcomes. The authors say comparisons with current screening methods, including evaluations of outcomes and cost, have not yet established their benefit.
Source: medicalxpress.com
